

RESEARCH

Open Access



Transcriptome-based biomarker gene screening and evaluation of the extracellular fatty acid-binding protein (Ex-FABP) on immune and angiogenesis-related genes in chicken erythrocytes of tibial dyschondroplasia

Ali Raza Jahejo^{1,2}, Sayyad Ali Raza Bukhari³, Nasir Rajput⁴, Nazeer Hussain Kalhoro⁵, Imdad Hussain Leghari⁴, Sayed Haidar Abbas Raza⁶, Zhen Li², Wen-zhong Liu^{1*} and Wen-xia Tian^{2*}

Abstract

Background: Tibial dyschondroplasia (TD) is a bone disorder in which dead chondrocytes accumulate as a result of apoptosis and non-vascularization in the tibial bone of broiler chickens. The pathogenicity of TD is under extensive research but is yet not fully understood. Several studies have linked it to apoptosis and non-vascularization in the tibial growth plate (GP). We conceived the idea to find the differentially expressed genes (DEGs) in chicken erythrocytes which vary in expression over time using a likelihood-ratio test (LRT). Thiram was used to induce TD in chickens, and then injected Ex-FABP protein at 0, 20, and 50 $\mu\text{g}\cdot\text{kg}^{-1}$ to evaluate its therapeutic effect on 30 screened immunity and angiogenesis-related genes using quantitative PCR (qPCR). The histopathology was also performed in TD chickens to explore the shape, circularity, arrangements of chondrocytes and blood vessels.

Results: Clinical lameness was observed in TD chickens, which decreased with the injection of Ex-FABP. Histopathological findings support Ex-FABP as a therapeutic agent for the morphology and vascularization of affected chondrocytes in TD chickens. qPCR results of 10 immunity (*TLR2*, *TLR3*, *TLR4*, *TLR5*, *TLR7*, *TLR15*, *IL-7*, *MyD88*, *MHCII*, and *TRAF6*) and 20 angiogenesis-related genes (*ITGAV*, *ITGA2*, *ITGB2*, *ITGB3*, *ITGA5*, *IL1R1*, *TBXA2R*, *RPL17*, *F13A1*, *CLU*, *RAC2*, *RAP1B*, *GIT1*, *FYN*, *IQGAP2*, *PTCH1*, *NCOR2*, *VAV-like*, *PTPN11*, *MAML3*) regulated when Ex-FABP is injected to TD chickens.

Conclusion: Immunity and angiogenesis-related genes can be responsible for apoptosis of chondrocytes and vascularization in tibial GP. Injection of Ex-FABP protein to thiram induced TD chickens decrease the chondrocytes damage and improves vascularization.

Keywords: Angiogenesis, Bone-deformity, Biomarker-genes, Broiler, Ex-FABP, Immunity

Background

Tibial dyschondroplasia (TD) is a leg bone deformity problem of broiler chicken that causes lameness. TD has a rising prevalence, and up to 30% of broiler flocks may be affected, and it is attributed to the death of chondrocytes due to low or no blood supply [1, 2]. Researchers are conducting in-depth research on TD

*Correspondence: wenzhongliu@sxau.edu.cn; wenxiatian@126.com

¹ College of Animal Science, Shanxi Agricultural University, Jinzhong 030801, China

² College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China

Full list of author information is available at the end of the article



to understand its pathogenicity. Although different aspects of TD occurrence have been well investigated since its report in 1965, its mechanism is still unclear [3]. Previously, TD was characterized by non-vascularized, un-mineralized, and non-viable cartilage in the tibial growth plate (GP), which failed to form bone [2, 4–6]. Therefore, any development regarding TD treatment is of utmost importance. It is very difficult to collect a large number of naturally occurring TD chickens for experimental purposes. Tetramethylthiuram disulfide (thiram) is a grain preservative often used in agriculture to induce artificial TD, often used to induce TD in chickens, which present the consistent results with natural TD [5, 7, 8]. Thiram affects the number of chondrocytes and destroys the normal proliferation, differentiation, and apoptosis of chondrocytes [1].

It has recently been reported that the extracellular fatty acid-binding protein (Ex-FABP) might have a therapeutic role in TD chickens [3] and osteoarthritic cartilage [9], which is upregulated during inflammation and reduces apoptosis [10]. It usually presents in chicken serum and represents the first extracellular protein able to selectively bind and transport fatty acid in extracellular fluids and blood [9]. However, the molecular impacts and therapeutic potential of the Ex-FABP protein are yet to be evaluated in TD chickens. This research assessed the therapeutic efficacy of Ex-FABP on TD chickens using histopathology and gene expression analysis. This experiment focused on the immunomodulatory function of chicken erythrocytes – the most common cells in circulation – before and after treatment with Ex-FABP based on the previous observation that TD regulates the expression of toll-like receptors (TLRs) 2, 3, 4, 5, and 21, as well as many immunological genes, including type I interferons (*IFN*) and interleukin (IL)-8 and angiogenesis-related genes such as integrins in TD induced chicken erythrocytes [11–13]. Multiple studies have reported the involvement of immunity and angiogenesis-related genes in thiram-induced TD chickens [12, 14]. Time scale regulation of gene expression needs to be explored, therefore initiated this two-phase experimental design; the first phase was based on a transcriptome sequencing analysis designed to classify differentially expressed biomarker genes on days 2, 6, and 15 after thiram treatment. The second phase of this study evaluated the mRNA expression of immunity and angiogenesis-related genes after the injection of Ex-FABP protein as a therapeutic intervention to thiram-induced TD chickens. Our findings will provide new evidence to understand the pathogenesis of TD and the therapeutic role of Ex-FABP in thiram-induced TD chicken.

Results

Differentially expressed genes (Phase 1)

The analysis of differentially expressed genes (DEGs) between thiram induced TD broiler chickens (T) and untreated control broiler chickens (C) for days 2, 6, and 15 were analyzed using the likelihood-ratio test (LRT) modeling approach (Additional file 1). The LRT analysis was performed on all the raw counts (Additional file 2), to investigate the interaction of time and treatment. The genes that differ significantly in expression between control and treatment over different periods (days) were considered DEGs. The results revealed that a total of 678 genes were differentially expressed ($P < 0.1$). The number of DEGs on 2 day vs 6 day, 2 day vs 15 day and 6 day vs 15 day were 249 (101 up, 148 down), 393 (180 up, 213 down), and 36 (27 up, 09 down) respectively (Fig. 1a). The degree of expression change of these DEGs between the two samples is shown as a volcano plot in Supplementary Fig. 1.

There were 19 commonly DEGs in all the comparisons (Additional file 4), the expressed genes were WD Repeat Domain 33 (*WDR33*), Cytokine inducible SH2 containing protein (*CISH*), Adenosine deaminase (*ADA*), B-cell lymphoma 2 (*Bcl-2*) like 1 (*BCL2L1*), COMM domain containing 7 (*COMMD7*), Zinc finger FYVE-type containing 27 (*ZFYVE27*), SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily a, member 1 (*SMARCA1*), Solute carrier family 35 member B2 (*SLC35B2*), Heat shock protein 90 alpha family class B member 1 (*HSP90AB1*), Eye-globin (*GBE*), ELKS/RAB6-interacting/CAST family member 1 (*ERC1*), TATA-box binding protein associated factor 4b (*TAF4B*), Uncharacterized LOC417973 (*LOC417973*), RUN domain containing 3A (*RUNDC3A*), Kruppel like factor 4 (*KLF4*), Uncharacterized protein (*VSIG10L*), Zinc finger protein 292 (*ZNF292*). Chicken_newGene_4083 and chicken_newGene_4973 lacks annotation in the database (Fig. 1b).

Protein-protein interaction of 19 common DEGs

Based on the STRING database, protein-protein interactions (PPIs) of 19 common biomarker genes were predicted (Supplementary Fig. 2). The network consists of high to low combined scores. After analysis, 2 nodes and 8 protein pairs were obtained with a medium confidence level (0.150). *BCL2L1* and *CISH* had the highest total score, 0.253. The second highest pair of *BCL2L1* and *KLF4* had a score of 0.184. The third composite score of the *BCL2L1* and *HSP90AB1* pair was 0.302. However, the lowest pair (*TAF4B* and *WDR33*) had a combined score of 0.427 (Additional file 6). The result demonstrated that *BCL2L1* was the most important amongst the 19 common DEGs, which could be responsible for causing





Fig. 1 a Analysis of DEGs that show significance in the interaction of time and treatment, using Venn diagrams. There were 249, 393, and 36 DEGs identified on the 6th day vs 2nd day (6T vs 2T), 15th day vs 2nd day (15T vs 2T), 15th day vs 6th day (15T vs 6T). In total 19 DEGs commonly expressed in 6T vs 2T, 15T vs 2T, 15T vs 6T. **b** Graphical presentation of 19 common DEGs showing the mean of gene expression without time effect on 6th day vs 2nd day (6T vs 2T), 15th day vs 2nd day (15T vs 2T), 15th day vs 6th day (15T vs 6T). Red color represents the control group, and the blue color represents the thiram group

apoptosis and non-vascularization in the thiram-induced tibial GP.

Gene ontology annotations

The gene ontology (GO) groups were allocated to a total of 678 DEGs (Additional file 7). Cytoplasmic vesicles (9 DEGs), intracellular vesicles (9 DEGs), and vesicles (9 DEGs) were the three enrichment groups of GO for 2 day vs 6 day and 6 day vs 15 day (Fig. 2a). The three enrichment categories of GO for 2 day vs 15 day were protein localization (14 DEGs), cell cycle (14 DEGs), cytoskeleton organization (14 DEGs) (Fig. 2b). The significance of genes related to cytoplasmic vesicle, intracellular vesicle, and vesicle in 2 day vs 6 day and 6 day vs 15 day reveal extreme fluctuations across different days (Fig. 2c). Moreover, the plot of DEGs in GO can be found with the *P* value ranked in Supplementary Fig. 3.

Analysis of potential KEGG pathways

The DEGs were annotated in different KEGG pathways (Additional file 9). The potential KEGG pathways for 2 day vs 6 day were the NOD-like receptor signaling pathway (6 genes) and biosynthesis of amino acids (4 genes) (Fig. 3a). The potential KEGG pathways of DEGs for 2 day vs 15 day were apoptosis (9 genes) and NOD-like receptor signaling pathway (7 genes) (Fig. 3b). The potential KEGG pathways of DEGs for 6 day vs 15 day were the NOD-like receptor signaling pathway (3 genes) and Glycosaminoglycan degradation (1 gene) (Fig. 3c). Moreover, the plot of KEGG pathways can be found with *P* value ranked in Supplementary Fig. 4.

Clinical observation and posture of chicken (Phase II)

The control group (A) of broiler chickens remained healthy and active throughout the experimental period without showing any signs of lameness. Group B and C, injected Ex-FABP and without thiram induction, show significantly good results. Thiram-induced TD broiler chicken group (D) showed several signs of depression, lameness, and failure to stand normally. Whereas broiler chickens in groups E and F, injected with Ex-FABP protein after thiram induction, expressed signs of recovery and significant improvements over group D, such as standing and walking. All the groups were evaluated on equilibrium condition (EC) scores for 6 and 15 days (Supplementary Fig. 5). The results suggest that the EC score was also significantly ($P < 0.05$) highest in group D for days 6 and 15 compared to other groups. However, the EC score was also significantly ($P < 0.05$) lower in groups E and F as compared to that of groups D and A (Fig. 4a-A).

Pathology and morphometry of tibial bone

The tibial bone of thiram-induced TD broiler chickens was severely affected on days 6, and 15 in group D. However, the broiler chickens injected with Ex-FABP protein (E and F) expressed signs of recovery and showed less tibial lesions and decreased lameness as compared to that of group D (Fig. 4b). The pathological results supported the posture position (equilibrium condition) and tibial bone morphometry results.

The average TD score (Fig. 4a-B), growth plate width (Fig. 4a-C), tibia mid-diameter (Fig. 4a-D), tibia-toe-length (Fig. 4a-E), and tibia length (Fig. 4a-F) was severely affected in thiram induced TD group as compared to that of the control group. The broiler chickens in groups E and F showed improvement in all morphometric measurements.

Histology and histomorphology of tibial bone

The histological examination of the tibial GP (Fig. 5a-C) revealed pyknosis and shortened nucleus in chondrocytes, and its pathological analysis showed the nucleus area of chondrocytes at days 6 and 15 in the thiram induced TD chicken group. However, the size and shape of chondrocytes and vascularization were normal in group A. The proliferation of chondrocytes was also affected mainly because of changes in size and shape. Moreover, the arrangements of chondrocytes became disordered in the pre-hypertrophic zone of thiram induced TD group, however, it recovered in Ex-FABP injection groups at days 6 and 15 (Fig. 5a-A). Similarly, angiogenesis also recovered in Ex-FABP injected groups (Fig. 5a-B).

The histomorphology of the microscopic figures was quantified with the ImageJ software, and the results of measurement of chondrocytes area (Fig. 5b-A), measurement of chondrocytes area in percentage (Fig. 5b-B), measurement of chondrocytes circularity (Fig. 5b-C), the relative area of blood vessels (Fig. 5b-D) and the density of blood vessels (Fig. 5b-E) suggests that thiram decreases the tibial bone vascularization and inhibits the growth of chondrocytes. The death of chondrocytes and changes in their structure were seen in thiram-induced TD group D. Moreover, the area, the density of blood vessels, and the circularity of chondrocytes improved in group E and F as compared to group D. We also observed that the blood vessels and chondrocytes began to recover in the Ex-FABP injection group on days 6 and 15 (Fig. 5b).

Immunity and angiogenesis-related genes confirmation using PCR

The identification of immune and angiogenesis-related genes in the chicken erythrocytes was carried out by PCR




Fig. 2 Gene ontology annotation of differentially expressed genes. **a** Up-regulated and down-regulated DEGs on 6th day vs 2nd day. **b** Up-regulated and down-regulated DEGs on 15th day vs 2nd day. **c** Up-regulated and down-regulated DEGs on 15th day vs 6th day. BP = biological process, CC = cellular process, MF = molecular functions. Counts = number of annotated genes




Fig. 3 KEGG annotation of differentially expressed genes. **a** KEGG annotation of DEGs up-regulated and down-regulated DEGs on 6th day vs 2nd day. **b** KEGG annotation of DEGs up-regulated and down-regulated DEGs on 15th day vs 2nd day. **c** KEGG annotation of DEGs up-regulated and down-regulated DEGs on 15th day vs 6th day

(Fig. 6). All the immunity-related genes (PCR products) fall in between the base pair 100-200bp, including toll-like receptors 2, 3, 4, 5, 7, and 15 (*TLR2*, *TLR3*, *TLR4*, *TLR5*, *TLR7*, *TLR15*), interleukin 7 (*IL-7*), tumor necrosis factor receptor (*TNFR*) related factor 6 (*TRAF6*), major histocompatibility complex II (*MHCII*), myeloid differentiation primary response 88 (*MyD88*).

All the angiogenesis-related genes (PCR products) fall in between the base pair 100-300bp, including integrin α -v precursor (*ITGAV*), integrin β -2 precursor (*ITGB2*), integrin subunit beta 2 (*ITGB2*), integrin β -3 precursor (*ITGB3*), integrin α -IIb-like (*ITGA5*), interleukin-1 receptor type 1 precursor (*IL1R1*), thromboxane A2 receptor (*TBXA2R*), ribosomal protein L17 (*RPL17*), coagulation factor XIII A chain protein (*F13A1*), clusterin precursor (*CLU*), ras-related C3 botulinum toxin substrate 2 (*RAC2*), ras-related protein Rap-1b precursor (*RAP1B*), ARF GTPase activating protein (*GIT1*), tyrosine-protein kinase Fyn-like (*FYN*), IQ motif containing GTPase activating protein 2 (*IQGAP2*), protein repair homolog 1 (*PTCH1*), nuclear receptor co-inhibitor 2 (*NCOR2*), proto-oncogene vav (*VAV-like*), tyrosine-protein phosphatase Non-receptor type 11 (*PTPN11*) and mastermind-like protein 3 (*MAML3*). Moreover, the original, full-length version of gel electrophoresis images can be found in Supplementary Fig. 6.

Protein-protein interaction of immunity and angiogenesis-related genes

PPIs of 30 immunity and angiogenesis-related genes were constructed and evaluated to predict their interactions. The network consists of high-low combined scores. A total of 2 nodes and 50 protein pairs obtained a low-confidence interaction score (0.150). MYD88 and TRAF6 had the highest combined score, 0.999. The second-highest combined score of TRAF6 and TLR4 was 0.997. ITGAV and ITGB3 had the third-highest overall score of 0.996 (Additional file 13).

In contrast, the last pair (*FYN* and *LOC419429*) had the lowest overall score of 0.41 (Supplementary Fig. 7). These results suggested the dominance of immunity-related genes when angiogenesis and immunity-related genes interact, as reflected by their best-combined score. It can be speculated that immunity-related genes are more important than angiogenesis-related genes, dependent on the immunity-related genes.




Fig. 4 a Estimation of the equilibrium condition and the tibia parameters in the thiram induced and Ex-FABP supplementing broiler chicken on days 6 and 15. Ex-FABP was injected in group A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively), D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F gave a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. ^{a-f} indicates significant differences ($P < 0.05$). (A) Estimation of the equilibrium condition, (B) tibial dyschondroplasia occurrence score, (C) measurement of growth plate width, (D) measurement of growth plate midline-diameter, (E) measurement of the tibia to toe length, (F) measurement of tibia length. b The clinical and pathological changes in the thiram induced and Ex-FABP supplementing broiler chicken groups of days 6 and 15. Ex-FABP was injected in group A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively), D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F were given a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. BV, blood vessels; GP, growth plate; TDL, tibial dyschondroplasia lesions; AC, articular cartilage

qPCR of immune and angiogenesis-related genes

We observed the effect of Ex-FABP on the expression of immunity and angiogenesis-related genes, specifically at days 6 and 15 using qPCR.

On day 6, the immunity-related genes *TLR2*, *TLR4*, *TLR5*, *TLR7*, *TLR15*, *MyD88*, *MHCII*, *TRAF6* were significantly downregulated ($P > 0.05$) in group D as compared to control group A. Whereas, and the same genes were significantly upregulated ($P < 0.05$) in the 50 $\text{mg}\cdot\text{kg}^{-1}$ Ex-FABP injected group F as compared to both groups D

and A. The immunity-related gene *IL-7* was significantly ($P < 0.05$) upregulated in group D while downregulated when supplemented with the 50 $\text{mg}\cdot\text{kg}^{-1}$ Ex-FABP protein as in group F. The higher expression of *IL-7* results suggested that the healing process is activated after the toxic effect of thiram. The process got reversed when Ex-FABP was injected. The angiogenesis-related genes *ITGAV*, *ITGB2*, *ITGB3*, *ITGA5*, *ILIR1*, *TBXA2R*, *F13A1*, *CLU*, *RAC2*, *RAP1B*, *GIT1*, *FYN*, *PTCH1*, *NCOR2*, *PTPN11*, and *MAML3* were significantly ($P < 0.05$) downregulated




Fig. 5 a Growth plate histomorphological changes of chondrocytes and blood vessels in the tibia (longitudinal section) for the thiram induced and Ex-FABP supplementing broiler chicken groups of days 6 and 15. Ex-FABP was injected in groups A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F were given a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. **(A)** H&E staining photographs of chondrocytes (Pre-hypertrophic zone) for days 6 and 15. NC, normal chondrocytes; DC, destroyed chondrocytes; RC, recovered chondrocytes. **(B)** H&E staining photographs of blood vessels (Hypertrophic zone) for days 6 and 15. NV, normal blood vessels; DV, destroyed blood vessels; RV, recovered blood vessels. **(C)** Zone-wise distribution of growth plate. AC, articular cartilage; PZ, proliferative zone; HZ, hypertrophic zone; CZ, calcification zone. **b** The histomorphological based quantification of chondrocytes and blood vessels for the thiram induced and Ex-FABP supplementing broiler chicken groups of days 6 and 15 using ImageJ software. Ex-FABP was injected in groups A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F gave a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. ^{a-f} indicates significant differences ($P < 0.05$). **(A)** Measurement of chondrocytes area (area= μm). **(B)** Measurement of chondrocytes area in percentage. **(C)** Measurement of chondrocytes circularity (area= μm). **(D)** The relative area of blood vessels. **(E)** The density of blood vessels

group D as compared to A. Moreover, the same genes were significantly ($P < 0.05$) upregulated in group F (Fig. 7a).

On day 15, TLR3 was also downregulated ($P > 0.05$) in addition to the previously described immunity-related genes in group D as compared to group A. Similar to what was observed at day 6, all of these genes were found to be significantly upregulated ($P < 0.05$) in the group F as compared to that of group D and group A. Same trend was found for *IL-7* as well. The angiogenesis-related genes *ITGAV*, *ITGA2*, *ITGB2*, *ITGB3*, *ITGA5*, *ILIR1*, *F13A1*, *CLU*, *RAC2*, *RAP1B*, *GIT1*, *FYN*, *IQGAP2*, *PTCH1*, *NCOR2*, *Vav 1 like PTPN11* and *MAML3* were significantly ($P < 0.05$) downregulated in group D as compared to group A. Moreover, the same genes were significantly ($P < 0.05$) upregulated in group F (Fig. 7b).

Discussion

TD is one of the major metabolic cartilage diseases in which the tibial GP cartilage fails to undergo osteogenic transition leading to the retention of thickened white opaque avascular cartilage plug [1, 15]. TD chickens were found with shrink cells, irregular chondrocyte columns, nuclear retraction, dissolution, and apoptosis [16]. Ex-FABP is reported to prevent vascularization and apoptosis therefore, we conceptualized its role in TD. We screened some biomarker genes based on transcriptome sequencing responsible for apoptosis and then selected immunity and angiogenesis-related genes to evaluate the




Fig. 6 Expression pattern of angiogenesis and immune-related 30 genes using gel electrophoresis

effect of Ex-FABP in the erythrocytes of thiram-induced TD chickens.

Differential expression analysis was performed using LRT as implemented in DESeq2. LRT finds genes differentially expressed between a full model and a reduced model. Our full model was “time + treatment + time: treatment” where “time: treatment denotes interaction effect between time and treatment. Our reduced model was “time + treatment”. The rationale of such a design was to understand the genes affected by the interaction of time and treatment. Our model finds the genes of which expression alters significantly over different periods (days). The effect imparted by only time was controlled in the model to purely assess the genes due to the interaction of time and treatment and not the time or treatment alone. Using such a model, we found 19 common differentially expressed genes, which are *WDR33*,

CISH, *ADA*, *BCL2L1*, *COMMD7*, *ZFYVE27*, *SMARCA1*, *SLC35B2*, *HSP90AB1*, *GBE*, *ERC1*, *TAF4B*, *LOC417973*, *RUNDC3A*, *KLF4*, *VSIG10L*, *ZNF292*.

Furthermore, we found that the most protein-protein interaction score belonged to *BCL2L1* compared to other genes, which stated that *BCL2L1* might play a major role in TD. Rath et al. [4] reported that the early effects of thiram on the GP might be the failure of genes encoding vascular endothelial growth factor (VEGF) receptors and Bcl-2 resulting from endothelial cell death, which compromise vascularization, cartilage remodeling, and the removal of dead chondrocytes leading to TD lesions. Similarly, we have also found that *BCL2L1* might be responsible for the apoptosis of chondrocytes and vascularization in the GP. We speculated that these common genes could cause apoptosis, further studying in our ongoing experiments.

(See figure on next page.)

Fig. 7 a Expression changes of chicken angiogenesis and immune-related 30 genes in the thiram induced and Ex-FABP supplementing broiler chicken groups of day 6. Ex-FABP was injected in groups A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F were given a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. ^{a-f} indicates significant differences ($P < 0.05$). **b** Expression changes of chicken angiogenesis and immune-related 30 genes in the thiram induced and Ex-FABP supplementing broiler chicken groups of day 15. Ex-FABP was injected in groups A, B, and C (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). D, E, and F (0, 20, 50 $\mu\text{g}\cdot\text{kg}^{-1}$ respectively). Whereas groups D, E, and F were given a diet containing 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram. ^{a-f} indicates significant differences ($P < 0.05$)




Fig. 7 (See legend on previous page.)

The second phase of this study was based on tibial bone histopathology. We evaluated the immunity and angiogenesis-related genes of chicken erythrocytes after the injection of Ex-FABP protein to thiram-induced TD chickens. Based on histopathological results, we found that thiram may cause erythrocytes to respond and to regulate the expression of immunity and angiogenesis-related genes resulting in apoptosis of chondrocytes. Previously, cartilage cell damage has been reported due to the apoptosis process and abnormal protein secretion in the cartilage cells [17, 18]. Moreover, thiram destroyed the regular columns of chondrocytes, decreasing its count, while Ex-FABP treatment enhanced that count [1, 19–21].

Moreover, the increase of fatty acids in the cellular microenvironment may increase the number of cells that undergo degradation and death during inflammation [22]. The binding of these fatty acids by Ex-FABP plays a key role in preventing chondrocyte apoptosis [10], and inhibiting the synthesis of Ex-FABP in different cell cultures can significantly reduce cell survival. Further reported that the apoptotic rate of chondrocytes and myogenic cells decreases when transfected with Ex-FABP cDNA, indicating that Ex-FABP can reduce apoptosis [10].

Our results demonstrate that broiler chicken erythrocytes can constitutively express 10 immune-related genes at the mRNA level, namely *TLR2*, *TLR3*, *TLR4*, *TLR5*, *TLR7*, *TLR15*, *IL-7*, *MyD88*, *MHCII*, and *TRAF6*. In addition, angiogenesis-related genes, namely *ITGAV*, *ITGA2*, *ITGB2*, *ITGB3*, *ITGA5*, *IL1R1*, *TBXA2R*, *RPL17*, *F13A1*, *CLU*, *RAC2*, *RAP1B*, *GIT1*, *FYN*, *IQGAP2*, *PTCH1*, *NCOR2*, *VAV-like*, *PTPN11*, and *MAML3*. Based on histopathology and mRNA results, it was speculated that Ex-FABP injection might regulate apoptosis and vascularization of tibial GP. To study the transcription of immune and angiogenesis-related genes in chicken erythrocytes of thiram-induced TD, we feed thiram to broilers at a concentration of 100 mg·kg⁻¹ and found that chondrocytes and vascular endothelial cells in the TD broiler GP undergo apoptosis. It has been reported in several studies that TLRs can cause cell apoptosis when viruses, bacteria, and toxins are found in the organism [23–25]. The transcription results of mRNA indicated that Ex-FABP protein might play a key role in preventing apoptosis induced by thiram. However, the specific molecular mechanism is still not explained.

We found that the *MyD88* gene was significantly upregulated on day 6 and downregulated on day 15 in group F. However, a study on the rat model evaluated that blocking *MyD88* can reduce apoptosis [26]. It could be speculated that apoptosis reduced on day 15. Similarly, up-regulation of *TRAF6* was also related to

apoptosis [27], which we found upregulated on day 6 and 15 in group F. *MHCII* reported to cause apoptosis, was found downregulated on day 15 [28]. *TLR7* that was downregulated on day 15 is also responsible for inducing apoptosis [29]. Similarly, activated *TLR4* on day 6 was downregulated on day 15 in group F. The activation of the *TLR4-MyD88* mediated by stress promotes apoptosis by angiotensin II [30]. Moreover, *TLR5* also had similar results, downregulated on day 15. *TLR5* may cause podocyte apoptosis [31]. Furthermore, *IL-7* can promote the survival of T cells by inactivating the death promoter (Bad) associated with the pro-apoptotic protein B-cell lymphoma 2 [32]. In-addition, inflammatory factors (such as endotoxin and IL-6) can induce the synthesis of Ex-FABP. On the other hand, the reduction of Ex-FABP synthesis results in a lack of proliferation and differentiation of chondrocytes and, ultimately, apoptosis of chondrocytes [10].

Thiram can also cause membrane damage, inactivate bone morphology and angioneclerosis [1, 33]. We found the expression of *CLU* to be very similar at both 6th and 15th days. It prevents apoptosis and necrosis caused by genotoxicity and oxidative stress [34]. Moreover, the *F13A1* protein coagulates blood when interacting with vascular endothelial growth factor receptor 2 (VEGFR2) and integrin $\alpha V\beta 3$. It plays a vital role in angiogenesis and tissue repairing [35]. *F13A1* was found upregulated on day 6 and 15 in Ex-FABP supplementary groups, which suggest tissue repairing is in process. Recent studies reported that *TBXA2R* is involved in platelet aggregation and activation, thereby activating various signal transduction cascades to control various cellular processes, such as smooth muscle vasoconstriction, response to inflammation, cell adhesion, movement, proliferation, and cell survival. Reports have further suggested dramatic cell killing when the level of *TBXA2R* downregulated [36, 37]. *TBXA2R* was found upregulated in group F on days 6 and 15. Transfection of chondrocytes and myoblasts with antisense Ex-FABP cDNA can inhibit cell proliferation and induce cell apoptosis. In addition, inflammatory stimuli and pathological conditions significantly increase the expression of Ex-FABP [38]. *IL1R1* is a cell surface receptor, a mediator of inflammation, and controls responses to injury or stress [39]. *IL1R1* was found upregulated on day 6 and downregulated on day 15, suggesting that tibial dyschondroplasia due to thiram induction causes injury gets reduced on day 15. It is reported that the ribosomal pathway is related to cell growth, proliferation, and apoptosis, which mediates the angiogenesis of injury or stress [40]. If the expression of *RPL17* is down-regulated, it will lead to VSMC proliferation; *RPL17* has a tumor suppressor effect [41]. However, in this study, we found that the expression of *RPL17* was

upregulated on days 6 and 15. Ex-FABP is also called a survival protein, which prevents apoptosis in the chondrocytes [10]. *RAC2* and *RAP1B* belong to the ras family, while *GIT1* and *IQGAP2* belong to the GTPase activating protein family. According to reports, the Ras family and GTPase activating protein family regulate angiogenesis [42]. However, we found that *RAC2* expression was significantly downregulated on day 6 and upregulated on day 15 in group F, suggesting that angiogenesis increased on day 15. This study evaluated integrin-related genes downregulated on the 6th and 15th days in thiram-treated chickens, which upregulated significantly ($P < 0.05$) when injecting 20 and 50 $\mu\text{g}\cdot\text{kg}^{-1}$ Ex-FABP. Our results are consistent with Mehmood et al. [5]. They studied the expression of *ITGB3* in chickens treated with thiram and found the downregulation of the *ITGB3* gene on the 14th day, which gets upregulated at the usage of ligustrazine.

Similarly, we found integrin genes, including *ITGB3*, regulated when injected Ex-FABP to thiram-induced TD chickens at day 15. Several studies have reported that integrins are involved in angiogenesis and are considered potential anti-angiogenic targets [43, 44]. High FABP5 expression enhances fatty acid transport to cancer cells used as a new energy source to meet the needs of rapid cell growth. In addition, excess fatty acids are transported into the nucleus, where they act as signal molecules to stimulate its nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma). PPAR gamma regulates genes that increase aggressiveness, resulting in decreased apoptosis and increased angiogenesis [45–48]. We observed a dramatic loss of cell viability and strong inhibition of cell proliferation and differentiation. However, when Ex-FABP was used to transfect chondrocytes, it could prevent cell apoptosis. It has also been reported by the study of Di Marco et al. [10], who suggest that Ex-FABP is a constitutive survival protein whose expression and activation are essential to protect cartilage cells from cell death.

Conclusion

In conclusion, chicken erythrocytes significantly express immunity (*TLR2*, *TLR3*, *TLR4*, *TLR5*, *TLR7*, *TLR15*, *IL-7*, *MyD88*, *MHCII*, and *TRAF6*) and angiogenesis-related genes (*ITGAV*, *ITGA2*, *ITGB2*, *ITGB3*, *ITGA5*, *IL1R1*, *TBXA2R*, *RPL17*, *F13A1*, *CLU*, *RAC2*, *RAP1B*, *GIT1*, *FYN*, *IQGAP2*, *PTCH1*, *NCOR2*, *VAV-like*, *PTPN11*, and *MAML3*) which may cause apoptosis of chondrocyte and vascularization in the GP. However, the injection of Ex-FABP protein in thiram-induced TD chickens prevents apoptosis and regulates angiogenesis. The most important genes found in this study are integrin and TLRs that may change the morphology of chondrocytes in the growth plate. In addition, we found 19 biomarker

genes, which may be related to the apoptosis of chondrocytes, such as the B-cell lymphoma 2 (*Bcl-2*) gene. These 19 (DEGs) genes will be studied in our ongoing experiments. It is recommended to inject 50 $\mu\text{g}\cdot\text{kg}^{-1}$ Ex-FABP protein on day 10 in broiler chickens to prevent TD. Our findings provide new evidence to understand the pathogenesis to prevent TD in the future.

Materials and methods

Experimental design

This study was divided into two phases.

The first phase was conducted to investigate the comparison between control and thiram-induced TD chickens of days 2, 6, and 15 based on transcriptome sequencing.

Broiler chickens were induced with TD in the second phase and divided into 6 and 15 days. The Ex-FABP protein was supplemented to TD chickens, followed by mRNA expression analysis of 30 biomarker genes related to angiogenesis and immunity. In addition, histomorphology of the tibia was performed.

Induction of TD and blood collection (Phase-1)

In the first phase, a total of 24 broiler chickens (a day-old) (Shanxi Daxiang Farming Community, Shanxi, China) were obtained and supplied *ad-libitum* feed and water. On the seventh day, broiler chickens were fed for 48 hours with 100 $\text{mg}\cdot\text{kg}^{-1}$ thiram to induce TD, following the instruction given by Tian et al. [7]. After the TD was induced for 48 hours, the controls (C) and thiram (T) groups were randomly allocated to all 24 broiler chickens differentiated as day 2, day 6, and day 15. Blood extracts were obtained from the brachial vein until scarification on days 2, 6, and 15.

RNA extraction, library construction, and RNA-Sequencing

The blood samples for the control and treatment groups were collected on days 2, 6, and 15. The total RNA was extracted from all samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) as previously described by Niu et al. [49]. As per manufacturer protocol, the library construction and RNA-Seq were performed at Beijing Bio Marker Technologies (Beijing, China). In brief, the purity of RNA was analyzed using a Nano Photometer spectrophotometer (IMPLEN, CA, USA). The concentration of extracted RNA was measured using Qubit RNA Assay Kit. in a Qubit 2.0 Fluorometer (Life Technologies, CA, USA) was used to measure the RNA concentration. Subsequently, the integrity of the RNA was assessed using the RNA Nano 6000 Assay Kit (Agilent Technologies, CA, USA). A total amount of 1 mg RNA per sample was used as input material for the RNA sample preparations. NEBNext Ultra™ RNA Library Prep Kit was used

to synthesize sequencing libraries (NEB, USA) following the manufacturer's recommendations. NEBNext Poly (A) mRNA Magnetic Isolation Module (NEB, E7490) was used to isolate mRNA from the total RNA. The cDNA library was constructed following the manufacturer's instructions of NEBNext Ultra RNA Library Prep Kit for Illumina (NEB, E7530) and NEBNext Multiplex Oligos for Illumina (NEB, E7500). In brief, the enriched mRNA was fragmented and used to synthesize the first-strand cDNA, followed by end-repair/dA-tail and adaptor ligation. Agencourt AMPure XP beads (Beckman Coulter, Inc.) were used to isolate suitable-sized fragments. Subsequently, the samples were treated with 3 μ L USER Enzyme (NEB, USA) 37°C for 15 minutes, followed by 5 minutes at 95°C before PCR. Universal PCR primers and Index (X) Primer were used to preserve the fidelity of the synthesized cDNA Phusion High-Fidelity DNA polymerase for subsequent PCR. Finally, the PCR items (AMPure XP system) were filtered, and the Agilent Bioanalyzer 2100 system was tested for library consistency. Eventually, the cDNA libraries were sequenced using an Illumina HiSeq™ 2500 sequencing device on a flow cell.

Transcriptome analysis using reference genome-based reads mapping

As a quality control step, adaptor sequences and low-quality sequences were cleaved using TrimGalore (version 0.6.6) (<https://github.com/FelixKrueger/TrimGalore>). The reads whose quality score was less than 20 in more than 20% of the bases were rejected. The clean reads were then mapped to the chicken genome (*Gallus gallus 5.0*) using Tophat2 [50] in the bash command-line interface. Raw counts of gene expression were counted using HTSeq (0.13.5). The raw counts were imported in R for differential gene expression using DESeq2.

Identification of differential gene expression

The DESeq2 (1.28.1) package was used for differential expression analysis in the R environment (4.0.3). Anders, Huber [51] provides a statistical model for determining the differential expression in the database using a model based on the negative binomial distribution. Benjamini and Hodgeberg was used to control the false discovery rate (FDR) to adjust the *P*value obtained. The likelihood ratio test (LRT) was used for the expression analysis. LRT finds differentially expressed genes between a full model and a reduced model. "Time + treatment + time: treatment" was our complete model, where "time: treatment" denotes the interaction of time and treatment. "Time + treatment" was our reduced model. This design was to understand the genes that are influenced by time and treatment. Our model finds genes that shift their expression dramatically over various periods. In the model, the

effect imparted by just time or just treatment was controlled to purely test the genes that are due to the interaction of time and treatment and not time alone.

Annotation of differentially expressed genes

The annotation of the DEGs was performed by gene set enrichment analysis as implemented in cluster Profiler (3.16.1) [52]. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation was performed with an enrichment *P*-value of < 0.1 [53]. The resulting annotations were plotted using ggplot2 (3.3.2) [54] or wrapper functions of cluster Profiler.

Protein-protein interaction (PPI) network construction

In order to find which gene or pair of the gene as protein interacts best within the 19 common DEGs, the STRING database was used for protein-protein interaction (PPI) following Mering et al. [55]. The STRING database is used to find the predicted PPI interaction based on the detail available in the database. This operating methodology for the database is based on the prediction process (neighborhood gene, gene fusion, co-occurrence, experiment co-expression, database, and text mining). In order to find their PPIs, we evaluated the typical 19 DEGs and used a combined score above > 0.9 as the cut-off point. The STRING database used a low confidence PPI (0150) (*Gallus gallus*).

Induction of TD and blood collection (Phase-2)

In the second phase, 120 broiler chickens (a day-old) were obtained from (Shanxi Daxiang Farming Community, Shanxi, China). Firstly, chickens were reared on *ad-libitum* feed and water for seven days. Then, all the birds were randomly distributed into 6 groups — A, B, C, D, E, and F; each group contains 20 birds. Subsequently, A, B, and C were treated with 0, 20, and 50 μ g kg^{-1} Ex-FABP protein, respectively, through the injected method. Additionally, D, E, and F were allocated for TD-induction and fed with 100 mg kg^{-1} thiram for 48 hours, as Tian et al. [7] recommended. Finally, TD-induced broiler chickens were injected with 0, 20, and 50 μ g kg^{-1} Ex-FABP protein for A, B, and C groups. After that, blood samples of 2.5 mL were taken from a brachial vein from each bird on days 6 and 15 before scarification.

The posture of chicken and tibial bone morphometry

All the broiler chickens were routinely checked as previously described by Alves et al. [56]. Photographs were taken to evaluate the equilibrium condition (EC), as shown in Supplementary Fig. 3. The body posture abnormality was evaluated on the score based, the perpendicular line that was drawn in front of the footpad;

score 1—leaned back and was highly erect, score 2—fell on the footpad area, score 3—prostrated equilibrium condition or a leaning forward posture/ unable to stand score 4—. Moreover, tibiae samples of 4 birds were taken at 6 and 15 post-day treatment. For morphological analysis, as described by Rath et al. [57], a Digital caliper (SATA91511, TATA Corporation, Shanghai, China) was prepared to measure the left sagittal section of the proximal tibial GP to measure the length and width of the tibia. Following Pines et al. [58] and Simsa et al. [59], the average TD score was calculated. Subsequently, the images were captured before and after the thiram treatment as per instructions are given by Rath et al. [57].

Histology and its quantification

For histological analysis, the left sagittal sections of the tibia were fixed in 4% paraformaldehyde [57]. Routine paraffin sections and hematoxylin and eosin staining were performed as described by Tian et al. [7]. Subsequently, the relative area of the blood vessel (the area of the region of interest divided by the total area to determine the percentage), as well as the quantified area of blood vessel density, chondrocytes cell roundness, and area of chondrocytes cell percentage, were measured according to the method of Fardin et al. [60] and, Jahejo et al. [12], in addition, the quantification of H&E staining was performed by ImageJ software (ImageJ 1.42q; Pixels 4080 to 3072). The equation “ $C = 4p (A/P^2)$ ” defined circularity; $p = \sim 3.14$ mathematical constant, $P =$ perimeter of the cell, and $A =$ area of the cell. The circularity value 1.0 indicates a perfectly circular shape, whereas the elongated polygon is indicated by the value 0.

Confirmation using quantitative real-time PCR

Besides morphological analysis, it was also necessary to reveal whether the supplementation with Ex-FABP protein in thiram-induced TD chickens also affects angiogenesis and immunity-related genes. Thus, we selected 30 angiogenesis and immunity-related biomarker genes as described by Jahejo et al. [14, 21]. We used Quant Studio™ 6 6’s TaKaRa SYBR Premix Ex Taq™ TM II (RR820A; Takara Bio Inc., Dalian, China). Each real-time PCR reaction included 1 µL of cDNA, 0.15 µL of each reverse and forward primer (10 pmol/µL), 6 µL SYBR Premix Ex Taq™ II, 0.1 µL of ROX dye II, and 2.6 µL of double H₂O distillate. The thermal cycles were followed as, 95 °C – 3 min, 42 cycles of 95 °C – 30 s, 55 °C – 30 s, and 72 °C – 10 s. Shanghai Generay Biotech Co Ltd synthesized primers, and their specific sequences and accession numbers are outlined in Table 1. The data from quantitative real-time PCR was calculated based on three biological and technical replicates, using the 2-Ct method.

Table 1 Details of primers used in this study

Genes	Primers	Accession NO.
<i>FL3A1</i>	F: GGATGCTTTTGGTCTGATAC R: CTGCTTGTGATCTCATTGG	NM_204685.1
<i>CLU</i>	F: CGTCAGTTCGGTTGGGTCTT R: CCTCGAGGTTGGGAGTTTTG	NM_204900.1
<i>TBXA2R</i>	F: GACAGCGAAGTGGAGATGAT R: GGAGAGTGGTCTGGATGATG	XM_015299775.1
<i>IL1R1</i>	F: TTTACGCACCATGAATCTG R: GAGCCGAGTTCACCTCAAT	NM_205485.1
<i>RPL17</i>	F: GTGAACAAGGCTCCAAAAT R: CGGTGAGGATCATCTCAATG	NM_001282277.1
<i>ITGB3</i>	F: TTTGTGGACAAGCCCATTTT R: CAAACATGGGCAAGCACTTT	NM_204315.1
<i>ITGAV</i>	F: TCAGTGGTTTGAGGATCTG R: AGGCTCTCGCTCTTGTTTTG	NM_205439.1
<i>ITGB2</i>	F: CAGTGCCTCAGCAATAAGA R: AGCACGACGAAACTTCACAT	NM_205251.1
<i>RAC2</i>	F: GGAGAATACATCCCCACTGT R: CCTCTTGCCAGCAGTATCC	NM_001201452.1
<i>ITGA2</i>	F: TGCTAATAATCCCCGTGTAG R: CAGATCTCCTCCCTGTTGAA	XM_015277561.1
<i>IQGAP2</i>	F: CTGGTGAGGCCAGTAAATTG R: CGCAAACCTCTGAATCGATGA	NM_001277778.1
<i>GIT1</i>	F: CATCACGCTGCAGGAGTACCT R: CTCATCGCTCAGGCTGTTGT	NM_204296.1
<i>VAV1</i>	F: CTGGAGACGTTGTAGGGTATG R: TGGTGAGACGGGTTGGTT	NT_469922.1
<i>ITGA5</i>	F: CTCCAACTACCCCGAGTACT R: CACCGAATAGCCCATATAAC	KC439457.1
<i>RAP1B</i>	F: TCGAGTCAAAGACACTGATG R: TAGGTTCTGACCTTGTCTCT	NM_001007852.1
<i>FYN</i>	F: AGGAGTGGTACTTCGGCAAA R: GTTTCACTTTCCCGGATCAG	NM_205349.2
<i>PTPN11</i>	F: TGGAGGCAGAAAATCTACTG R: CGCCTAACAGAGAGAGTGAA	NM_204968.1
<i>PTCH1</i>	F: TTCCTTCTAGCCCATGCGTTT R: CTACACTTGCTCCTGTTCCGCTTT	NM_204960.2
<i>NCOR2</i>	F: GGTCCACACACTTGAC R: GGTGGATACTAGGATGGATT	XM_015275621.1
<i>MAML3</i>	F: GCAACCACACGCTGATCATG R: CCATCGCAAATCCATTCTG	XM_015276692.1
<i>MHCII</i>	F: TGCCCGAAACCGACCGTCTG R: TCCAGCACCACCAGCACCTG	NM_001318995
<i>MyD88</i>	F: CAGAAAGACCTTCAGTTTGT R: AATGACGACCACCATCCTCC	NM_001030962
<i>TLR2</i>	F: ACCTGGCCATAACAGGATA R: ATGGAGCTGATTTGGTTGGA	AB046119
<i>TLR3</i>	F: GCCTAAATATCACGGTACTC R: CACAACAGTGGTAGTGATCA	NM_001011691

Table 1 (continued)

Genes	Primers	Accession NO.
TLR4	F: GCCCTGAGGGAAACAACAG	NM_001030693
	R: CACCAAGGTGAATCTTTGCA	
TLR5	F: CTGCCAAATCTTCGTGCTTT	FJ915552
	R: ACAGACGGAGTATGGTCAAA	
TLR7	F: GGTGTAGCCACGTGCTTAG	NM_001011688
	R: CCATCCCTGTGCTGATAGAG	
TLR15	F: GTGTCCAACGTCCATCGT	NM_001037835
	R: GAAGCATGGAAATCCGATTG	
IL-7	F: CTTGTTCTGTGCCAGTGAA	NM_001037833
	R: CTTGATGTCATGGCTGAGT	
TRAF6	F: ATGGAAGCCAAGCCAGAGTT	XM015287208
	R: ACAGCGCACCAAGGGTAT	

F Forward, R Reverse

Protein-protein interaction (PPI) network construction

In order to find which gene or pair of the gene as protein interacts best within the list of screened immunity and angiogenesis-related genes, the STRING database was used for PPIs following the experiment of Mering et al. [55]. The STRING database was used to find the predicted PPIs interaction based on the detail available in the database. This database working method is on the prediction (neighborhood gene, gene fusion, co-occurrence, experiment co-expression, database, and text mining). We analyzed the immunity and angiogenesis-related genes to find their PPIs, a combined score above > 0.9 was used as the cut-off value. A low confidence PPI (0.150) was used in the STRING database (*Gallus gallus*).

Statistical analysis

The data was expressed as mean and standard deviation (mean \pm SD). A value of $P < 0.05$ was considered statistically significant. Use JMP (version 10) software for statistical analysis.

Abbreviations

TD: Tibial dyschondroplasia; ITGAV: Integrin alpha-v precursor; CLU: Clusterin precursor; DEGs: Differentially expressed genes; MAPK: Mitogen-activated protein kinase; TLR2: Toll-like receptors 2; TLR3: Toll-like receptors 3; TLR4: Toll-like receptors 4; TLR5: Toll-like receptors 5; TLR7: Toll-like receptors 7; TLR15: Toll-like receptors 15; IL-7: Interleukin 7; TNFR6: Tumor necrosis factor receptor (TNFR) related factor 6; MHCII: Major histocompatibility complex II; MyD88: Myeloid differentiation primary response 88; TBXA2R: Thromboxane A2 receptor; IL1R1: Interleukin-1 receptor type 1 precursor; RPL17: Ribosomal protein L17; ITGB3: Integrin beta-3 precursor; ITGB2: Integrin beta-2 precursor; RAC2: Ras-related C3 botulinum toxin substrate 2; ITGA2: Integrin alpha-2; IQGAP2: IQ motif containing GTPase activating protein 2; G1T1: ARF GTPase-activating protein; VAV1: Proto-oncogene vav; ITGA5: Integrin alpha-IIb-like; RAP1B: Ras-related protein Rap-1b precursor; FYN: Tyrosine-protein kinase Fyn-like; PTPN11: Tyrosine-protein phosphatase non-receptor type 11; PTCH1: Protein patched homolog 1; NCOR2: Nuclear receptor corepressor 2; MAML3: Mastermind-like protein

3; ATP2A3: Sarcoplasmic/endoplasmic reticulum calcium ATPase 3; UBE2R2: Ubiquitin-conjugating enzyme E2 R2; CCSAP: Centriole cilia and spindle-associated protein; F13A1: Coagulation factor XIII A chain protein; SHROOM2: Shroom2 isoform X6; RASA3: Ras GTPase-activating protein 3; Thiram: Tetramethyl thiuram disulfide; GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; VEGF: Vascular endothelial growth factor signaling pathway; VEGFR2: Vascular endothelial growth factor receptor 2; WDR33: WD Repeat Domain 33; CISH: Cytokine inducible SH2 containing protein; ADA: Adenosine deaminase; BCL2L1: BCL2 like 1; COMMD7: COMM domain containing 7; ZFYVE27: Zinc finger FYVE-type containing 27; SMARCA1: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1; SLC35B2: Solute carrier family 35 member B2; HSP90AB1: Heat shock protein 90 alpha family class B member 1; GBE: Eye-globin; ERC1: ELKS/RAB6-interacting/CAST family member 1; TAF4B: TATA-box binding protein associated factor 4b; LOC417973: Uncharacterized LOC417973; RUNDC3A: RUN domain containing 3A; KLF4: Kruppel like factor 4; VSIG10L: Uncharacterized protein; ZNF292: Zinc finger protein 292.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12864-022-08494-9>.

Additional file 1.

Additional file 2.

Additional file 3.

Additional file 4.

Additional file 5.

Additional file 6.

Additional file 7.

Additional file 8.

Additional file 9.

Additional file 10.

Additional file 11.

Additional file 12.

Additional file 13.

Additional file 14.

Authors' contributions

WZL and WXT conceived and designed the experiments; SARB and ARJ analyzed the data; ARJ and ZL performed the experiments; ARJ suggested the analyses; ARJ wrote the paper; ARJ, SHAR, NHK, NR, IHL and WZL revised the manuscript. All authors read and approved the final draft of the manuscript.

Funding

This work was supported by the Fund for Shanxi "1331 Project" (20211331-13), the Shanxi Scholarship Council of China (2017-073), the Key scientific and technological innovation platform of Jinzhong (P171002-3), The National Key R & D Program (2016YFD0500800), Key Technologies R & D Program of Shanxi Province (20130311027-3), the National Natural Science Foundation of China (31072179) and "131" leading talent project of Colleges and universities in Shanxi province. All these funds provided financial support in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets generated during the current study are not publicly available on the repository. We have got raw read counts from the sequencing company, which are the same as those generated by HTSeq-counts or feature-counts. The data generated or analyzed during this study are included in this published article and its supplementary information files, Additional files 1, 2, 4, 6, 7, 9, and 13.

Declarations

Ethics approval and consent to participate

All experiments were approved and performed in accordance with the guidelines and regulations of the Institutional Animal Care and Use Committee of Experimental Animal Management at the Shanxi Agricultural University, China (Approval No SXAU-EAW-2019Br.002003). Notably, all experiments were performed as per the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹College of Animal Science, Shanxi Agricultural University, Jinzhong 030801, China. ²College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China. ³Department of Biotechnology, University of Sargodha, Sargodha, Pakistan. ⁴Department of Poultry Husbandry, Sindh Agriculture University, Tandojam, Pakistan. ⁵Sindh Institute of Animal Health, Karachi, Pakistan. ⁶College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China.

Received: 15 May 2021 Accepted: 23 March 2022

Published online: 22 April 2022

References

- Zhang H, Mehmood K, Jiang X, Yao W, Iqbal M, Waqas M, et al. Effect of tetramethyl thiram disulfide (thiram) in relation to tibial dyschondroplasia in chickens. *Environ Sci Pollut Res Int.* 2018;25:28264–74.
- Mehmood K, Zhang H, Li K, Wang L, Rehman MU, Nabi F, et al. Effect of tetramethylpyrazine on tibial dyschondroplasia incidence, tibial angiogenesis, performance and characteristics via HIF-1 α /VEGF signaling pathway in chickens. *Sci Rep.* 2018;8:1–10.
- Jahejo AR, Tian WX. Cellular, molecular and genetical overview of avian tibial dyschondroplasia. *Res Vet Sci.* 2021;135:569–79.
- Rath NC, Huff WE, Huff GR. Thiram-induced changes in the expression of genes relating to vascularization and tibial dyschondroplasia. *Poult Sci.* 2007;86:2390–5.
- Mehmood K, Zhang H, Jiang X, Yao W, Tong X, Iqbal MK, et al. Ligustrazine recovers thiram-induced tibial dyschondroplasia in chickens: Involvement of new molecules modulating integrin beta 3. *Ecotoxicol Environ Saf.* 2019;168:205–11.
- Iqbal M, Zhang H, Mehmood K, Li A, Jiang X, Wang Y, et al. Icaria: a Potential Compound for the Recovery of Tibial Dyschondroplasia Affected Chicken Via Up-Regulating BMP-2 Expression. *Biol Proc Online.* 2018;20:15.
- Tian WX, Li JK, Qin P, Wang R, Ning GB, Qiao JG, et al. Screening of differentially expressed genes in the growth plate of broiler chickens with tibial dyschondroplasia by microarray analysis. *BMC Genomics.* 2013;14:276.
- Mehmood K, Zhang H, Yao W, Jiang X, Waqas M, Li A, et al. Protective effect of Astragaloside IV to inhibit thiram-induced tibial dyschondroplasia. *Environ Sci Pollut Res Int.* 2019;26:16210–9.
- Descalzi Cancedda F, Dozin B, Zerega B, Cermelli S, Cancedda R. Extracellular fatty acid binding protein (ex-FABP) is a stress protein expressed during chondrocyte and myoblast differentiation. *Osteoarthritis Cart.* 2001;9(Suppl A):S118–22.
- Di Marco E, Sessarego N, Zerega B, Cancedda R, Descalzi CF. Inhibition of cell proliferation and induction of apoptosis by exFABP gene targeting. *J Cell Physiol.* 2003;196:464–73.
- Paolucci S, Barjesteh N, Wood RD, Sharif S. Chicken erythrocytes respond to Toll-like receptor ligands by up-regulating cytokine transcripts. *Res Vet Sci.* 2013;95:87–91.
- Jahejo AR, Zhang D, Niu S, Mangi RA, Khan A, Qadir MF, et al. Transcriptome-based screening of intracellular pathways and angiogenesis related genes at different stages of thiram induced tibial lesions in broiler chickens. *BMC Genomics.* 2020;21:50.
- Workenhe ST, Kibenge MJ, Wright GM, Wadowska DW, Groman DB, Kibenge FS. Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes. *Virology.* 2008;376:36–43.
- Jahejo AR, Jia FJ, Raza SHA, Shah MA, Yin JJ, Ahsan A, et al. Screening of toll-like receptor signaling pathway-related genes and the response of recombinant glutathione S-transferase A3 protein to thiram induced apoptosis in chicken erythrocytes. *Dev Comp Immunol.* 2021;114:103831.
- Zhang H, Mehmood K, Li K, Rehman MU, Jiang X, Huang S, et al. Icaria Ameliorate Thiram-Induced Tibial Dyschondroplasia via Regulation of WNT4 and VEGF Expression in Broiler Chickens. *Front Pharmacol.* 2018;9:123.
- Zhang H, Mehmood K, Jiang X, Li Z, Yao W, Zhang J, et al. Identification of differentially expressed miRNAs profile in a thiram-induced tibial dyschondroplasia. *Ecotoxicol Environ Saf.* 2019;175:83–9.
- Velada I, Capela-Silva F, Reis F, Pires E, Egas C, Rodrigues-Santos P, et al. Expression of genes encoding extracellular matrix macromolecules and metalloproteinases in avian tibial dyschondroplasia. *J Comp Pathol.* 2011;145:174–86.
- Shim MY, Karnuah AB, Anthony NB, Pesti GM, Aggrey SE. The effects of broiler chicken growth rate on valgus, varus, and tibial dyschondroplasia. *Poult Sci.* 2012;91:62–5.
- Zhang H, Mehmood K, Jiang X, Yao W, Iqbal M, Li K, et al. Effect of Icaria on Tibial Dyschondroplasia Incidence and Tibial Characteristics by Regulating P2RX7 in Chickens. *Biomed Res Int.* 2018;2018:6796271.
- Nabi F, Li K, Shahzad M, Han Z, Zhang D, Liu J, et al. Gambogic acid inhibits Hsp90 expressions in thiram-induced tibial dyschondroplasia. *Pak Vet J.* 2016;36:224–6.
- Jahejo AR, Rajput N, Kashif J, Kalhor DH, Niu S, Qiao ML, et al. Recombinant glutathione-S-transferase A3 protein regulates the angiogenesis-related genes of erythrocytes in thiram induced tibial lesions. *Res Vet Sci.* 2020;131:244–53.
- Cancedda FD, Dozin B, Zerega B, Cermelli S, Cancedda R. Ex-FABP: a fatty acid binding lipocalin developmentally regulated in chicken endochondral bone formation and myogenesis. *Biochimica et Biophysica Acta (BBA)-Protein Struct Mol Enzymol.* 2000;1482:127–35.
- Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. *EMBO J.* 2000;19:3325–36.
- López M, Sly LM, Luu Y, Young D, Cooper H, Reiner NE. The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. *J Immunol.* 2003;170:2409–16.
- Into T, Kiura K, Yasuda M, Kataoka H, Inoue N, Hasebe A, et al. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF- κ B activation. *Cell Microbiol.* 2004;6:187–99.
- Ha T, Hua F, Li Y, Ma J, Gao X, Kelley J, et al. Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. *Am J Physiol Heart Circulatory Physiol.* 2006;290:H985–94.
- Yuan P, Liu Z, Liu M, Huang J, Li X, Zhou X. Up-regulated tumor necrosis factor-associated factor 6 level is correlated with apoptosis in the rat cerebral ischemia and reperfusion. *Neuro Sci.* 2013;34:1133–8.
- Nagy ZA, Mooney NA. A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. *J Mol Med.* 2003;81:757–65.
- Yu D-S, Wu C-L, Ping S-Y, Keng C, Shen K-H. Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation. *The Kaohsiung J Med Sci.* 2015;31:391–7.
- Lu J, Jia R, Yang D, Zhu J, Ding G. Candestart attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. *Biochem Biophys Res Commun.* 2009;380:81–6.
- Lin X, Huang H, You Y, Tang C, Gu X, Huang M, et al. Activation of TLR5 induces podocyte apoptosis. *Cell Biochem Funct.* 2016;34:63–8.
- Li WQ, Jiang Q, Khaled AR, Keller JR, Durum SK. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. *J Biol Chem.* 2004;279:29160–6.
- Beckmann R, Houben A, Tohidnezhad M, Kweider N, Fragoulis A, Wruck CJ, et al. Mechanical forces induce changes in VEGF and VEGFR-1/SFlt-1 expression in human chondrocytes. *Int J Mol Sci.* 2014;15:15456–74.

34. Song HB, Jun HO, Kim JH, Yu YS, Kim KW, Min BH, et al. Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells. *Oncol Rep.* 2013;30:2713–8.
35. Gemmati D, Vigliano M, Burini F, Mari R, El Mohsein HH, Parmeggiani F, et al. Coagulation Factor XIIIa (F13A1): Novel Perspectives in Treatment and Pharmacogenetics. *Curr Pharmaceut Design.* 2016;22:1449–59.
36. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. *Cellular Signal.* 2004;16:521–33.
37. Orr K, Buckley NE, Haddock P, James C, Parent J-L, McQuaid S, et al. Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). *Oncotarget.* 2016;7:55458.
38. Gentili C, Tutolo G, Zerega B, Di Marco E, Cancedda R, Cancedda FD. Acute phase lipocalin Ex-FABP is involved in heart development and cell survival. *J Cell Physiol.* 2005;202:683–9.
39. Kato H, Matsumine A, Wakabayashi T, Hasegawa M, Sudo A, Shintani K, et al. Large-scale gene expression profiles, differentially represented in osteoarthritic synovium of the knee joint using cDNA microarray technology. *Biomarkers.* 2007;12:384–402.
40. Zhou X, Liao WJ, Liao JM, Liao P, Lu H. Ribosomal proteins: functions beyond the ribosome. *J Mol Cell Biol.* 2015;7:92–104.
41. Smolock EM, Korshunov VA, Glazko G, Qiu X, Gerloff J, Berk B. Ribosomal protein L17, Rpl17, is an inhibitor of vascular smooth muscle growth and carotid intima formation. *Circulation.* 2012;126:2418–27.
42. Yan J, Li F, Ingram DA, Quilliam LA. Rap1a is a key regulator of fibroblast growth factor 2-induced angiogenesis and together with Rap1b controls human endothelial cell functions. *Mol Cell Biol.* 2008;28:5803–10.
43. Dohn MR, Kooker CG, Bastarache L, Jessen T, Rinaldi C, Varney S, et al. The gain-of-function integrin $\beta 3$ Pro33 variant alters the serotonin system in the mouse brain. *J Neurosci.* 2017;1482–17.
44. Liao Z, Kasirer-Friede A, Shattil SJ. Optogenetic interrogation of integrin $\alpha V\beta 3$ function in endothelial cells. *J Cell Sci.* 2017;jcs.205203.
45. Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, et al. A novel cutaneous Fatty Acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells. *Genes & Cancer.* 2013;4:297–314.
46. Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, et al. The expression of C-FABP and PPARgamma and their prognostic significance in prostate cancer. *Int J Oncol.* 2014;44:265–75.
47. Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, et al. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. *Cancer Res.* 2001;61:4357–64.
48. Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. *Oncogene.* 2003;22:2739–49.
49. Niu S, Wang CX, Jia FJ, Jahejo AR, Li X, Ning GB, et al. The expression of prostaglandins-related genes in erythrocytes of broiler chicken responds to thiram-induced tibial dyschondroplasia and recombinant glutathione-S-transferase A3 protein. *Res Vet Sci.* 2019;124:112–7.
50. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol.* 2013;14:R36.
51. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol.* 2010;11:R106.
52. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omic: J Integrative Biol.* 2012;16:284–7.
53. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG Ref Resource Gene Protein annotation. 2016;44:D457–D62.
54. Wickham H. ggplot2: elegant graphics for data analysis. Springer; 2016.
55. Cv M, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. *Nucleic Acids Res.* 2003;31:258–61.
56. Alves MCF, Paz ICLA, Nääs IA, Garcia RG, Caldara FR, Baldo GAA, et al. Locomotion of commercial broilers and indigenous chickens. *Revista Brasileira de Zootecnia.* 2016;45:372–9.
57. Rath NC, Huff WE, Balog JM, Huff GR. Comparative efficacy of different dithiocarbamates to induce tibial dyschondroplasia in poultry. *Poult Sci.* 2004;83:266–74.
58. Pines M, Hasdai A, Monsonogo-Ornan E. Tibial dyschondroplasia—tools, new insights and future prospects. *World's Poult Sci J.* 2005;61:285–97.
59. Simsa S, Hasdai A, Dan H, Ornan EM. Induction of tibial dyschondroplasia in turkeys by tetramethylthiuram disulfide (thiram). *Poult Sci.* 2007;86:1766–71.
60. Fardin M, Rossier O, Rangamani P, Avigan P, Gauthier N, Vonnegut W, et al. Cell spreading as a hydrodynamic process. *Soft Matter.* 2010;6:4788–99.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

